Abstract

The purpose of the Developmental Research Program of the MSKCC SPORE in Prostate Cancer is to support innovative translational research projects in prostate cancer. This program will allow us to respond quickly to new opportunities in translational research.
The specific aims of the DRP are:
Aim 1. To provide seed funding for innovative, investigator-initiated research in the etiology, prevention, diagnosis, and treatment of prostate cancer Aim 2. To fund research with exceptional potential to advance the translational research goals of the SPORE. This mechanism will allow the SPORE leadership to respond rapidly to new research opportunities.
Aim 3. To establish a mechanism for strategic interactions with other SPOREs and other major national and international research centers The Executive Committee will prioritize pilot projects for support based on novelty and programmatic need resulting from the Committee's review of work presented at our research meetings, including the Prostate Cancer Working Group (weekly), SPORE Scientific Seminar Series (monthly), Genitourinary Disease Management Team (monthly), Multi-institutional Prostate Cancer Program Retreat (annual), and the MSKCC Geoffrey Beene Cancer Research Center Retreats (annual). This ensures the steady infusion of new ideas and techniques into our SPORE in Prostate Cancer program. Preference will be given to projects that complement the long-term research goals of the SPORE and advance our translational research objectives. The Executive Committee can also solicit and fund experimental or clinical initiatives that address an urgent and specific need in the MSKCC SPORE in Prostate Cancer program or a unique research opportunity.

Public Health Relevance

As a public health concern, prostate cancer is the second deadliest cancer in men. The translational research projects in this program aim to use knowledge of animal and human prostate cancer biology to develop and test interventions related to the prevention, early detection, diagnosis, prognosis, and treatment of prostate cancer in men.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092629-16
Application #
9148029
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-14
Project End
2021-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
16
Fiscal Year
2016
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Puca, Loredana; Bareja, Rohan; Prandi, Davide et al. (2018) Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 9:2404
Currall, Benjamin B; Chen, Ming; Sallari, Richard C et al. (2018) Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet 27:4194-4203
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Audenet, François; Vertosick, Emily A; Fine, Samson W et al. (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199:961-968
Hugosson, Jonas; Godtman, Rebecka Arnsrud; Carlsson, Sigrid V et al. (2018) Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52:27-37
Kohestani, Kimia; Chilov, Marina; Carlsson, Sigrid V (2018) Prostate cancer screening-when to start and how to screen? Transl Androl Urol 7:34-45
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Kim, Kwanghee; Watson, Philip A; Lebdai, Souhil et al. (2018) Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clin Cancer Res 24:2408-2416

Showing the most recent 10 out of 505 publications